Chemical optimization of arylomycins results in an inhibitor of bacterial type I signal peptidase that shows activity both against multidrug-resistant clinical isolates of Gram-negative bacteria in vitro and in several in vivo infection models.
- Peter A. Smith
- Michael F. T. Koehler
- Christopher E. Heise